Automating Portal’s cell engineering platform using Multiply Labs’ robotic systems aims to reduce costs and accelerate timelines, in support of cell therapy scalability and accessibility CAMBRIDGE, ...

Portal Biotechnologies and Multiply Labs announced a collaboration with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more ...

Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Retro Biosciences (Retro), a ...

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first collaboration with a major cell therapy developer. Multiply Labs and Legend ...

Multiply Labs, a San Francisco-based robotics company developing advanced automated manufacturing systems for cell therapies, announced an expansion of its collaboration with Thermo Fisher Scientific.

Multiply Labs, a robotics firm, and Retro Biosciences, which is developing therapies to address age-related diseases, signed an agreement valued at up to $85 million to automate Retro’s approach to ...

Leishmaniasis is a parasitic disease that affects up to 1 million people worldwide each year. It is caused by the protozoan Leishmania, transmitted through the bite of a sandfly. Once inside its ...